tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- J. Pharmacol. Exp. Ther. (1)
- Am. J. Physiol. Renal Physiol. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Iwasaki K et al. | Pharmacokinetic study of FK 506 in the rat. | 1991 | Transplant. Proc. | pmid:1721268 |
| Kay JE et al. | Uptake of FK 506 by lymphocytes and erythrocytes. | 1991 | Transplant. Proc. | pmid:1721269 |
| Jain AB et al. | Comparative study of cyclosporine and FK 506 dosage requirements in adult and pediatric orthotopic liver transplant patients. | 1991 | Transplant. Proc. | pmid:1721270 |
| Abu-Elmagd KM et al. | Four-hour versus 24-hour intravenous infusion of FK 506 in liver transplantation. | 1991 | Transplant. Proc. | pmid:1721271 |
| Dumont FJ et al. | Up-regulation of gene expression by FK 506. | 1991 | Transplant. Proc. | pmid:1721300 |
| Rao P et al. | Effect of FK 506 on FK-binding protein and transforming growth factor beta gene expression. | 1991 | Transplant. Proc. | pmid:1721301 |
| DiLella AG and Craig RJ | Characterization of the human FKBP-12 gene and related pseudogenes. | 1991 | Transplant. Proc. | pmid:1721302 |
| Borg AJ and Kumagai M | FK 506 and xenogeneic human anti-porcine cellular reactivity. | 1991 | Transplant. Proc. | pmid:1721332 |
| Fung J et al. | A randomized trial of primary liver transplantation under immunosuppression with FK 506 vs cyclosporine. | 1991 | Transplant. Proc. | pmid:1721333 |
| Winkler M et al. | Use of FK 506 for treatment of chronic rejection after liver transplantation. | 1991 | Transplant. Proc. | pmid:1721334 |
| D'Alessandro AM et al. | FK 506 rescue therapy for resistant rejection episodes in liver transplant recipients. | 1991 | Transplant. Proc. | pmid:1721335 |
| de Paulis A et al. | Characterization of the anti-inflammatory effect of FK-506 on human mast cells. | 1991 | J. Immunol. | pmid:1721644 |
| Jensen CW et al. | Pediatric renal transplantation under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1721364 |
| McCauley J et al. | The question of FK 506 nephrotoxicity after liver transplantation. | 1991 | Transplant. Proc. | pmid:1703344 |
| Jordan ML et al. | FK 506 conversion of renal allografts failing cyclosporine immunosuppression. | 1991 | Transplant. Proc. | pmid:1721365 |
| Alessiani M et al. | Infections in adult liver transplant patients under FK 506 immunosuppression. | 1991 | Transplant. Proc. | pmid:1703345 |
| Offner G et al. | FK 506 in a 14-year-old renal allograft recipient with cyclosporine-related liver nephrotoxicity: 1-year follow-up. | 1991 | Transplant. Proc. | pmid:1721366 |
| Imai K et al. | Histopathological study of canine pancreaticoduodenal allotransplantation with FK506, cyclosporine, and triple regimen immunosuppression. | 1991 | Transplant. Proc. | pmid:1703347 |
| Carroll PB et al. | FK 506-associated diabetes mellitus in the pediatric transplant population is a rare complication. | 1991 | Transplant. Proc. | pmid:1721396 |
| Freise CE et al. | Similar clinical presentation of neurotoxicity following FK 506 and cyclosporine in a liver transplant recipient. | 1991 | Transplant. Proc. | pmid:1721397 |
| Eidelman BH et al. | Neurologic complications of FK 506. | 1991 | Transplant. Proc. | pmid:1721398 |
| Fukuzawa M et al. | Effect of donor-specific transfusion and FK 506 on small intestine allotransplantation. | 1991 | Transplant. Proc. | pmid:1721427 |
| Ogasa N et al. | Effect of FK 506 on growth of transplanted newborn rat intestine. | 1991 | Transplant. Proc. | pmid:1721428 |
| de Bruin RW et al. | Fulminant graft-versus-host disease after FK 506 treatment in fully allogeneic small bowel transplantation. | 1991 | Transplant. Proc. | pmid:1721429 |
| Langrehr JM et al. | FK 506 inhibits nitric oxide production by cells infiltrating sponge matrix allografts. | 1991 | Transplant. Proc. | pmid:1721430 |
| Markus PM et al. | Effects of in vivo treatment with FK506 on natural killer cells in rats. | 1991 | Transplantation | pmid:1707562 |
| Lin CS et al. | FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes. | 1991 | Cell. Immunol. | pmid:1707760 |
| Vincent SH et al. | Effects of the immunosuppressant FK-506 and its analog FK-520 on hepatic and renal cytochrome P450 mixed-function oxidase. | 1991 | Biochem. Pharmacol. | pmid:1708254 |
| Kitahara S et al. | Lymphoproliferative disorders after FK 506. | 1991 | Lancet | pmid:1708846 |
| McCauley J et al. | FK 506 in the management of transplant-related nephrotic syndrome and steroid-resistant nephrotic syndrome. | 1991 | Transplant. Proc. | pmid:1721459 |
| Carrieri G et al. | Effect of FK 506 in the prophylaxis of autoimmune glomerulonephritis in NZB/WF1 mice. | 1991 | Transplant. Proc. | pmid:1721460 |
| Deguchi K et al. | Effects of FK 506 on acute experimental allergic encephalomyelitis. | 1991 | Transplant. Proc. | pmid:1721461 |
| Vathsala A et al. | The immunosuppressive antagonism of low doses of FK506 and cyclosporine. | 1991 | Transplantation | pmid:1713361 |
| Kawano K et al. | A protective effect of FK506 in ischemically injured rat livers. | 1991 | Transplantation | pmid:1713362 |
| Armitage JM et al. | Preliminary experience with FK506 in thoracic transplantation. | 1991 | Transplantation | pmid:1713363 |
| Steeves M et al. | In-vitro interaction of a novel immunosuppressant, FK 506, and antacids. | 1991 | J. Pharm. Pharmacol. | pmid:1717676 |
| Hildebrandt A et al. | FK 506: short- and long-term treatment after cardiac transplantation in nonhuman primates. | 1991 | Transplant. Proc. | pmid:1703694 |
| Unmasking immunosuppression. | 1991 | Lancet | pmid:1717800 | |
| Ericzon BG et al. | Effect of FK 506 on glucose metabolism in the cynomolgus monkey: studies in pancreatic transplant recipients and nontransplanted animals. | 1991 | Transplant. Proc. | pmid:1703695 |
| Markus PM et al. | Prevention of graft-versus-host disease following allogeneic bone marrow transplantation in rats using FK506. | 1991 | Transplantation | pmid:1718063 |
| Kumano K et al. | FK 506-induced nephrotoxicity in rats. | 1991 | Transplant. Proc. | pmid:1703696 |
| Gordon RD et al. | Liver transplantation at the University of Pittsburgh, 1984 to 1990. | 1991 | Clin Transpl | pmid:1726458 |
| Ryu S and Yasunami Y | The necessity of differential immunosuppression for prevention of immune rejection by FK506 in rat islet allografts transplanted into the liver or beneath the kidney capsule. | 1991 | Transplantation | pmid:1718064 |
| Kuroki H et al. | Morphological and immunological analysis of rats with long-term-surviving limb allografts induced by a short course of FK 506 or cyclosporine. | 1991 | Transplant. Proc. | pmid:1703697 |
| Jamieson NV et al. | Orthotopic liver transplantation at Addenbrooke's Hospital Cambridge 1968 to 1991. | 1991 | Clin Transpl | pmid:1726459 |
| Starzl TE et al. | Hepatotrophic properties in dogs of human FKBP, the binding protein for FK506 and rapamycin. | 1991 | Transplantation | pmid:1718068 |
| Morris RE et al. | Use of rapamycin for the suppression of alloimmune reactions in vivo: schedule dependence, tolerance induction, synergy with cyclosporine and FK 506, and effect on host-versus-graft and graft-versus-host reactions. | 1991 | Transplant. Proc. | pmid:1703698 |
| Takahara S et al. | Survival of cardiac allograft in highly sensitized and nonsensitized rats treated with FK506. | 1991 | J Clin Lab Immunol | pmid:1726566 |
| Stötter H and Lotze MT | Human lymphokine-activated killer cell activity. Role of IL-2, IL-4, and IL-7. | 1991 | Arch Surg | pmid:1726819 |
| Karlsson H and Nässberger L | FK506 lacks the ability to inhibit expression of interleukin-2 receptor beta-chain on human lymphocytes. | 1991 | J Clin Lab Immunol | pmid:1726895 |